Septerna, Inc. 8K

Septerna, Inc. announced Q2 2026 financial results and pipeline updates, including progress in its SEP-479 Phase 1 trial, broader portfolio development, and a cash runway expected to extend at least into 2029.

On August 10, 2026, Septerna, Inc. reported its business progress and financial results for the quarter ended June 30, 2026, highlighting continued advancement of its clinical and discovery pipeline—including an ongoing Phase 1 trial for SEP-479 for hypoparathyroidism with pharmacokinetic data supporting once-daily dosing and SAD/MAD readout expected in Q1 2027, strategic reevaluation of development paths for SEP-631 in mast cell-driven diseases, and progress toward a development candidate in its TSHR NAM program—while also disclosing a strong cash position of $516.5 million (projected to fund operations at least into 2029), substantial collaboration revenue from its Novo Nordisk partnership, increased R&D and G&A spending, and a reduced quarterly net loss of $13.0 million versus the prior year period.

Filing Facts

CIK

1984086

Ticker

SEPN

Form

8K

Source Type

fda

Accession

0001193125-26-342328

Alert Tier

6